Chong Kun Dang Pharmaceutical Corp.
Symbol: 185750.KS
KSC
101200
KRWTržní cena dnes
6.4696
Poměr P/E
-0.0542
Poměr PEG
1.29T
MRK Cap
- 0.01%
Výnos DIV
Chong Kun Dang Pharmaceutical Corp. (185750-KS) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 365065.3 | 155861.2 | 187332.6 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 145418.9 | 38444.3 | 55519.9 | |||||||||||
balance-sheet.row.net-receivables | 0 | 311468.6 | 287306.6 | 234703.7 | |||||||||||
balance-sheet.row.inventory | 0 | 261431.9 | 270081.5 | 224722.9 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 8606.1 | 365.5 | 20387.9 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 946571.9 | 713614.8 | 667147.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 319787.1 | 310697.4 | 298909.7 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 67179.1 | 5565.5 | -22146.7 | |||||||||||
balance-sheet.row.tax-assets | 0 | 14213.2 | 6208.6 | 2350.3 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2150.1 | 61843.5 | 79634.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 455856.6 | 411268 | 379552.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.account-payables | 0 | 183938.8 | 145436.3 | 129327.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 184767.4 | 124445.5 | 102091.4 | |||||||||||
balance-sheet.row.tax-payables | 0 | 43938.2 | 29026.4 | 18701.1 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 30000 | 111292.6 | 134962.3 | |||||||||||
Deferred Revenue Non Current | 0 | 1484.8 | 6438.3 | 5982 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 134996.6 | 98922.3 | 20691.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 75327.4 | 129380.9 | 160660.6 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 4996.5 | 1694.2 | 3470.5 | |||||||||||
balance-sheet.row.total-liab | 0 | 586793.3 | 503594 | 480890.4 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 31421.2 | 29970.1 | 28565.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | 218102.4 | 376370.8 | 302106.6 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 350829.8 | 276706.4 | 250156.9 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 215341.1 | -60654.3 | -14818.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 815694.5 | 622393.1 | 566010 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | -59.3 | -1104.3 | -200.3 | |||||||||||
balance-sheet.row.total-equity | 0 | 815635.2 | 621288.8 | 565809.6 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 212598 | 44009.8 | 33373.2 | |||||||||||
balance-sheet.row.total-debt | 0 | 219763.9 | 235738.1 | 237053.8 | |||||||||||
balance-sheet.row.net-debt | 0 | 117.5 | 118321.2 | 105241.1 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 212521.2 | 79977.8 | 42356.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 36942.2 | 33597.7 | 27481.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 29681.8 | -77299.3 | -71568.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -29559.7 | -51435.9 | -6926 | |||||||||||
cash-flows.row.inventory | 0 | -5980.3 | -54466.2 | -53770.6 | |||||||||||
cash-flows.row.account-payables | 0 | 38583.8 | 15824.5 | -15597.8 | |||||||||||
cash-flows.row.other-working-capital | 0 | 26638 | 12778.2 | 4725.7 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 39014.7 | 31458.4 | 14634.2 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 451.6 | 142.1 | -3448.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -192468.2 | -57181.1 | -61266.4 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 89470 | 44375.6 | 21934.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 39.8 | 347.8 | 3815.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -171312.9 | -65380.3 | -90809.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -22714.6 | -0.3 | -896.2 | |||||||||||
cash-flows.row.common-stock-issued | 0 | -3335.3 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -6025 | -1888.4 | -1935.3 | |||||||||||
cash-flows.row.dividends-paid | 0 | -11608.5 | -11238.8 | -10808.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | -16.5 | -3212.4 | 98778.7 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -43700 | -16339.8 | 85138.9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -917.6 | -410.1 | 920.1 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 102229.4 | -14395.8 | 8153.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 219646.3 | 117416.9 | 131812.7 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 117416.9 | 131812.7 | 123659.1 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 318159.9 | 67734.5 | 12903.9 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 249353.9 | 14669.8 | -38940.5 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1669404.4 | 1488344.7 | 1343559.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1014059.9 | 945705.3 | 847741.1 | |||||||||||
income-statement-row.row.gross-profit | 0 | 655344.5 | 542639.4 | 495818.3 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 408657.6 | 432733.3 | 401059.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1422717.5 | 1378438.7 | 1248800.7 | |||||||||||
income-statement-row.row.interest-income | 0 | 5789.3 | 2139 | 716.2 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 36942.2 | 34919.3 | 18187.3 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 246686.9 | 109906.1 | 94758.7 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 241403 | 97165.1 | 80593.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 27995.7 | 17187.3 | 38237.4 | |||||||||||
income-statement-row.row.net-income | 0 | 212521.2 | 80953.4 | 42720.4 |
Často kladené otázky
Co je Chong Kun Dang Pharmaceutical Corp. (185750.KS) celková aktiva?
Chong Kun Dang Pharmaceutical Corp. (185750.KS) celková aktiva jsou 1402428435512.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.530.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je 19599.181.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.122.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.146.
Co je Chong Kun Dang Pharmaceutical Corp. (185750.KS) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 212521171440.000.
Jaký je celkový dluh podniku?
Celkový dluh je 219763880100.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 408657610015.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.